Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
7(41%)
Results Posted
67%(4 trials)

Phase Distribution

Ph phase_3
2
12%
Ph phase_4
7
41%
Ph not_applicable
3
18%
Ph phase_2
4
24%

Phase Distribution

0

Early Stage

4

Mid Stage

9

Late Stage

Phase Distribution16 total trials
Phase 2Efficacy & side effects
4(25.0%)
Phase 3Large-scale testing
2(12.5%)
Phase 4Post-market surveillance
7(43.8%)
N/ANon-phased studies
3(18.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

17

all time

Status Distribution
Active(11)
Completed(6)

Detailed Status

Completed6
Recruiting5
Not yet recruiting4
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
17
Active
7
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (25.0%)
Phase 32 (12.5%)
Phase 47 (43.8%)
N/A3 (18.8%)

Trials by Status

recruiting529%
completed635%
not_yet_recruiting424%
active_not_recruiting212%

Recent Activity

7 active trials
Showing 5 of 17
recruitingphase_4

SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery

NCT05812755
active_not_recruitingphase_2

A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction

NCT05806138
completedphase_2

The Impact of Vericiguat on Microvascular Function in Patients With Documented Vasospastic Angina Pectoris

NCT06415227
completed

Vericiguat and Exercise Hemodynamics in Patients With HFrEF

NCT07697365
recruitingnot_applicable

Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

NCT06239974
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT05812755Phase 4

SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery

Recruiting
NCT05806138Phase 2

A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction

Active Not Recruiting
NCT06415227Phase 2

The Impact of Vericiguat on Microvascular Function in Patients With Documented Vasospastic Angina Pectoris

Completed
NCT07697365

Vericiguat and Exercise Hemodynamics in Patients With HFrEF

Completed
NCT06239974Not Applicable

Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

Recruiting
NCT07668739Phase 4

Efficacy of Verciguat in TR and RV Failure

Not Yet Recruiting
NCT07594509Not Applicable

Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery

Not Yet Recruiting
NCT07405944Phase 4

Vericiguat and Reverse Remodeling Indices in Heart Failure

Recruiting
NCT05711719Phase 2

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

Completed
NCT05093933Phase 3

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

Completed
NCT05704478Phase 4

Impact of Vericiguat on Hemodynamics of Heart Failure

Active Not Recruiting
NCT05420012Phase 4

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

Completed
NCT06601465Phase 2

COgnitioN With VERiciGuat Evaluation in Heart Failure

Recruiting
NCT07047547Not Applicable

A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure

Recruiting
NCT06812546Phase 4

Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction

Not Yet Recruiting
NCT06671990Phase 4

The CardioMEMS Vericiguat Heart Failure Trial

Not Yet Recruiting
NCT02861534Phase 3

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17